Multiomics Data Integration — PatSnap Eureka
Multiomics Data Integration: Patent & Research Landscape 2026
Multiomics data integration combines genomics, transcriptomics, proteomics, metabolomics, and epigenomics into unified biological models. This report maps 75+ patent and literature records from 2008–2025, covering core computational clusters, application domains, and emerging AI frontiers.
Four Foundational Challenges Defining Multiomics Integration
Multiomics data integration encompasses four foundational computational challenges: handling high-dimensional, heterogeneous data across platforms with incompatible scales and formats; aligning samples or features across omics layers (vertical and horizontal integration); extracting biologically interpretable signals from integrated datasets; and enabling reproducible, FAIR-compliant data management and sharing.
The dataset spans publications and patents from 2008 through 2025, with the bulk of innovation activity concentrated between 2016 and 2023. Retrieved records describe integration approaches operating on genomics, transcriptomics, proteomics, metabolomics, epigenomics (DNA methylation, histone modification), microbiomics, and chromatin accessibility data (ATAC-seq). Two filed patents — both from The Medical College of Wisconsin — directly claim machine learning-based multiomics integration architectures.
Core technical sub-domains include statistical and mathematical integration frameworks, network-based integration approaches, machine learning and deep learning models, single-cell multi-omics integration, cloud and big data infrastructure for omics pipelines, and FAIR data management and visualization platforms. PatSnap’s analytics platform enables systematic mapping of these sub-domains across the global patent corpus.
Four Integration Clusters Across the Innovation Corpus
Records in this dataset organise into four distinct computational clusters, each with different maturity profiles and patent activity levels.
Statistical & Dimension Reduction Integration
The most established cluster, spanning the full timeline from 2014 to 2022. Methods project multiple omics datasets into shared latent spaces to identify correlated variance structures. Representative tools include Multiple Co-Inertia Analysis (MCIA) applied to the NCI-60 cancer cell panel, the STATegra pipeline validated against TCGA cancer datasets, and PathwayMultiomics for matched and unmatched sample analysis.
Foundational · Highest method countNetwork-Based Integration
Uses molecular interaction networks — protein–protein interaction, gene regulatory, or metabolic networks — as scaffolding to integrate heterogeneous omics signals. It is the most frequently cited approach in disease pathway discovery. Mergeomics integrates GWAS, EWAS, TWAS, and functional genomics data through marker set enrichment and key driver analysis. IntOMICS applies Bayesian regulatory network inference integrating gene expression, DNA methylation, and copy number variation.
Disease pathway discovery · Bayesian methodsMachine Learning & Deep Learning Integration
The fastest-growing cluster in the dataset, with most entries from 2019 onward. Methods range from classical supervised classification to transformer-based attention mechanisms and graph neural networks. The Medical College of Wisconsin’s patent claims generation of feature data indicating connections between proteomics and other omics layers using ML model interpretation. IE-MOIF employs self-attention to capture intrinsic correlations of omics features, with attention embedding used for biomarker visualization.
Fastest-growing · Active patent frontierSingle-Cell Multi-Omics Integration
A distinct and rapidly maturing sub-domain focused on simultaneous measurement and integration of multiple modalities at single-cell resolution, including scRNA-seq with ATAC-seq, CITE-seq, and Multiome data. GLUE demonstrated multi-omics human cell atlas construction over millions of cells. A 2023 benchmarking study evaluated 12 integration methods across six analytical dimensions, signalling a move toward standardised evaluation criteria.
Highest velocity · 12 methods benchmarkedTechnology Cluster Activity & Application Domain Distribution
Visual summary of cluster activity spans and application domain coverage derived from the retrieved dataset.
Technology Cluster Active Spans
ML/DL is the fastest-growing cluster; single-cell methods are the most recent entrant.
Application Domain Coverage
Oncology is the dominant application domain; microbiome and precision medicine are growing clusters.
Developmental Staging: From Infrastructure to AI Interpretability
The dataset reveals clear developmental staging across four periods, from early data warehousing through to explainable AI for biomedical multiomics.
IP Positioning, Freedom-to-Operate & Emerging Risks
Key strategic signals derived from the patent and literature corpus for R&D teams and IP strategists.
Patent Density Is Low Relative to Published Methods
With only 3 patent records in this dataset against dozens of published tools and frameworks, the multiomics integration space remains significantly under-patented. R&D teams and commercial platform developers have substantial freedom-to-operate but also opportunity to file claims on novel ML architectures, integration pipelines, and interpretability methods before consolidation occurs.
Machine Learning Integration Is the Active Patent Frontier
The Medical College of Wisconsin’s filings represent the clearest IP positioning in this dataset around ML and multiomics. Organisations building clinical decision support tools or diagnostic platforms using multiomics and AI should monitor this family closely and evaluate differentiation strategies, particularly around model interpretability and cross-layer feature mapping.
Five Frontiers Signalled in 2021–2025 Records
The most recent patent filing — Multiomic data integration with machine learning and model interpretation by The Medical College of Wisconsin (US, expected grant 2025) — signals formal IP consolidation around ML-based feature interaction mapping across omics layers, specifically claiming generation of “model interpretation data” and “feature data indicating interactions between biomolecules across omics layers.” This reflects a shift from black-box ML toward explainable AI for biomedical multiomics.
IE-MOIF (2023) employs self-attention to capture intrinsic correlations of omics features, with attention embedding used directly for biomarker visualisation, mirroring broader adoption of transformer architectures from NLP in biological sequence and feature modelling. GLUE (2021) demonstrated multi-omics human cell atlas construction over millions of cells, and a 2023 benchmarking study evaluated 12 integration methods across six analytical dimensions.
A 2022 study established the first matched DNA/RNA/protein/metabolite reference suites from a family quartet, enabling ground-truth benchmarking — a prerequisite for regulatory-grade clinical multiomics. Longitudinal and dynamic integration methods address time-course multi-omics, increasingly important for tracking disease progression, drug response, and microbiome dynamics over time. PatSnap’s life sciences solutions support monitoring of these emerging IP clusters. Further context on global omics infrastructure investment is available from EMBL-EBI and NIH.
- AI/ML model interpretability: Medical College of Wisconsin dual filing (WO 2023; US 2025) claims explainable feature interaction mapping
- Attention mechanisms and transformer architectures: IE-MOIF self-attention for omics feature correlations and biomarker visualisation (2023)
- Single-cell multi-omics at scale: GLUE million-cell atlas; 12 methods benchmarked across six analytical dimensions (2023)
- Reference materials and standardised benchmarking: First matched DNA/RNA/protein/metabolite reference suites from a family quartet (2022)
- Longitudinal and dynamic integration: Hybrid multi-omics networks with node propagation for temporal regulatory inference (2021)
Patent Assignees and Jurisdictional Distribution
| Assignee | Jurisdiction | Filings | Focus | Status |
|---|---|---|---|---|
| The Medical College of Wisconsin, Inc. | US / WO | 2 | ML-based multiomics integration with model interpretation; feature data indicating connections between proteomics and other omics layers | WO/2023 granted; US/2025 pending |
| INDX Technology (India) Private Limited | WO | 1 | System and method for performing multi-omics data integration | 2021 PCT filing |
| Dodamani, Shrikant (individual inventor) | IN | 1 | Bioinformatics approach for integrating multi-omics data sets; biomarker identification and therapeutic target discovery | 2024 IN filing, pending |
Multiomics Data Integration — key questions answered
Multiomics data integration refers to the computational and analytical approaches that combine two or more omics layers — genomics, transcriptomics, proteomics, metabolomics, epigenomics, and beyond — into unified models of biological systems.
The four foundational challenges are: (1) handling high-dimensional, heterogeneous data across platforms with incompatible scales and formats; (2) aligning samples or features across omics layers; (3) extracting biologically interpretable signals from integrated datasets; and (4) enabling reproducible, FAIR-compliant data management and sharing.
Among the patent records retrieved, The Medical College of Wisconsin holds 2 filings (WO/2023 and US/2025 pending) directed at ML-based multiomics integration. INDX Technology (India) Private Limited holds 1 WO filing (2021), and individual inventor Shrikant Dodamani holds 1 pending IN filing (2024).
Single-cell multi-omics integration is the highest-velocity technical sub-domain, with novel methods including GLUE, Liam, and UMINT, and benchmarking of 12 competing methods signalling a move toward standardised evaluation criteria and scalable integration for atlas-scale projects.
The dominant application domain is oncology and complex disease characterisation, including cancer subtyping and therapeutic target identification. Other domains include precision medicine and biomarker discovery, microbiome and microbial systems biology, translational and clinical research platforms, and plant and animal systems biology.
Multiple records address reproducibility, data sharing standards, and FAIR principles. Organisations building commercial platforms should treat FAIR-compliant data management not as an optional feature but as a table-stakes requirement for clinical and translational partnerships, particularly in EU jurisdictions.
PatSnap Eureka searches patents and research literature to answer instantly.